Trial record 2 of 2 for:    MMY3013

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03180736
Recruitment Status : Recruiting
First Posted : June 8, 2017
Last Update Posted : April 13, 2018
Janssen Research & Development, LLC
Information provided by (Responsible Party):
European Myeloma Network

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 1, 2021
  Estimated Study Completion Date : July 1, 2023